FY2020 EPS Estimates for Catalent Inc Lowered by Analyst (CTLT)

Catalent Inc (NYSE:CTLT) – Analysts at William Blair dropped their FY2020 earnings estimates for shares of Catalent in a report issued on Monday, April 15th. William Blair analyst J. Kreger now expects that the company will post earnings per share of $1.69 for the year, down from their previous forecast of $1.84.

A number of other brokerages have also commented on CTLT. Morgan Stanley boosted their price target on shares of Catalent from $46.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday. First Analysis restated an “outperform” rating and set a $49.00 price target on shares of Catalent in a research note on Tuesday, March 5th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Wednesday, February 6th. TheStreet upgraded shares of Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. Finally, ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent presently has an average rating of “Buy” and a consensus target price of $49.57.

NYSE:CTLT opened at $42.75 on Thursday. The firm has a market capitalization of $6.47 billion, a PE ratio of 26.89, a P/E/G ratio of 2.43 and a beta of 1.69. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63. Catalent has a twelve month low of $29.23 and a twelve month high of $46.43.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.08. The company had revenue of $623.00 million during the quarter, compared to analyst estimates of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. Catalent’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.45 EPS.

Large investors have recently modified their holdings of the stock. Sageworth Trust Co purchased a new position in shares of Catalent in the 1st quarter worth about $32,000. Quantamental Technologies LLC purchased a new position in shares of Catalent in the 4th quarter worth about $47,000. Bremer Trust National Association purchased a new position in shares of Catalent in the 4th quarter worth about $54,000. Enlightenment Research LLC purchased a new position in shares of Catalent in the 4th quarter worth about $56,000. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of Catalent by 3,074.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock worth $58,000 after buying an additional 1,742,199 shares during the last quarter. 99.82% of the stock is currently owned by institutional investors.

In related news, insider Aristippos Gennadios sold 3,392 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $42.18, for a total value of $143,074.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Lance Miyamoto sold 43,619 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,326 shares of company stock valued at $2,303,676. Company insiders own 1.40% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: Understanding the different types of bonds

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit